Form 4: AN2 Therapeutics Executive Sanjay Chanda Reports Stock and Option Transactions
SEC Form 4 Filing
Sanjay Chanda, Chief Development Officer of AN2 Therapeutics, reports acquisition and disposal of common stock and stock options.
Summary
- On February 26, 2025, Sanjay Chanda, the Chief Development Officer of AN2 Therapeutics, reported transactions involving the company's stock and options.
- Chanda acquired 50,250 shares of common stock and disposed of 80,074 shares.
- These transactions included the acquisition of 100,500 stock options with an exercise price of $1.13, exercisable starting February 25, 2035.
- The reported transactions reflect changes in Chanda's direct ownership of AN2 Therapeutics securities.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing detailing stock transactions by an officer. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors regarding the buying and selling activities of company executives and directors.
Stakeholder Impact
- Shareholders are informed about the transactions of a key executive, providing insight into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Start date for vesting of restricted stock units (RSUs) and stock options. |
| February 26, 2025 | Date of the reported transactions. |
| February 25, 2035 | Expiration date for stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.